Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Mol Cancer Res. 2011 Mar 7;9(4):418–429. doi: 10.1158/1541-7786.MCR-10-0511

Figure 3.

Figure 3

Stable depletion of EZH2 reduces tumorigenicity of human melanoma cells. (A) Reduced colony formation following EZH2 depletion. Representative photomicrographs shown of anchorage-independent colonies 20 days after initiating growth of EZH2 shRNA cells (shE) and control shRNA cells (shN1) in soft agar. (B) Mean colonies per field. Error bars represent standard deviation of 3 independent platings. p < 0.01 (**) for the difference between shN1 and shE by Students’s t-test. (C) Reduced tumor volumes in NOD/SCID mice injected with EZH2 shRNA cells compared to control shRNA cells. Each data point represents the mean volume (±SEM) of subcutaneous tumor xenografts developing in 12 mice per experimental group. p < 0.00001 for the difference between shE and shN1 tumor growth curves by repeated measures analysis of variance. (D) Expression of SA-β-gal is observed in xenograft tumor specimen from EZH2 shRNA tumor (upper panel, right), but not from control tumor (upper panel, left). EGFP expression (lower panels) confirms continued expression of the shRNA construct in the xenograft cells. Results are representative of two tumors analyzed. Scale bar,50 μM.